Clinical response according to FCGR3A and FCGR2A genotypes
| . | FCGR3A . | FCGR2A . | ||||||
|---|---|---|---|---|---|---|---|---|
| VV, n (%) . | VF, n (%) . | FF, n (%) . | P . | HH, n (%) . | HR, n (%) . | RR, n (%) . | P . | |
| Response to induction | ||||||||
| Whole series | ||||||||
| CR | 23 (34) | 75 (35) | 61 (35) | .86 | 41 (34) | 75 (34) | 38 (38) | .21 |
| CRu | 21 (31) | 69 (32) | 57 (33) | 31 (26) | 85 (38) | 28 (28) | ||
| CR/CRu | 44 (65) | 144 (67) | 118 (68) | 72 (60) | 160 (72) | 66 (66) | ||
| PR | 21 (31) | 61 (29) | 46 (26) | 43 (36) | 53 (24) | 30 (30) | ||
| SD/PD | 3 (4) | 8 (4) | 10 (6) | 5 (4) | 11 (4) | 5 (5) | ||
| R-CHOP regimen | ||||||||
| CR/CRu | 36 (67) | 121 (69) | 103 (71) | .29 | 62 (64) | 131 (72) | 60 (69) | .55 |
| PR | 18 (33) | 48 (27) | 34 (23) | 32 (33) | 43 (24) | 23 (26) | ||
| SD/PD | 0 (0) | 6 (3) | 8 (6) | 2 (3) | 5 (4) | 3 (5) | ||
| Response at 2 y | ||||||||
| Observation arm | ||||||||
| CR/CRu | 15 (58) | 37 (43) | 44 (59) | .19 | 21 (43) | 43 (45) | 28 (59) | .17 |
| PR | 4 (15) | 11 (13) | 5 (6) | 5 (10) | 7 (7) | 7 (15) | ||
| SD/PD | 7 (27) | 38 (44) | 26 (35) | 20 (41) | 39 (41) | 11 (23) | ||
| Maintenance arm | ||||||||
| CR/CRu | 21 (72) | 72 (77) | 55 (80) | .61 | 43 (77) | 76 (73) | 27 (73) | .93 |
| PR | 4 (14) | 8 (8) | 3 (4) | 3 (5) | 9 (9) | 3 (8) | ||
| SD/PD | 4 (14) | 14 (15) | 11 (16) | 7 (13) | 14 (14) | 6 (16) | ||
| . | FCGR3A . | FCGR2A . | ||||||
|---|---|---|---|---|---|---|---|---|
| VV, n (%) . | VF, n (%) . | FF, n (%) . | P . | HH, n (%) . | HR, n (%) . | RR, n (%) . | P . | |
| Response to induction | ||||||||
| Whole series | ||||||||
| CR | 23 (34) | 75 (35) | 61 (35) | .86 | 41 (34) | 75 (34) | 38 (38) | .21 |
| CRu | 21 (31) | 69 (32) | 57 (33) | 31 (26) | 85 (38) | 28 (28) | ||
| CR/CRu | 44 (65) | 144 (67) | 118 (68) | 72 (60) | 160 (72) | 66 (66) | ||
| PR | 21 (31) | 61 (29) | 46 (26) | 43 (36) | 53 (24) | 30 (30) | ||
| SD/PD | 3 (4) | 8 (4) | 10 (6) | 5 (4) | 11 (4) | 5 (5) | ||
| R-CHOP regimen | ||||||||
| CR/CRu | 36 (67) | 121 (69) | 103 (71) | .29 | 62 (64) | 131 (72) | 60 (69) | .55 |
| PR | 18 (33) | 48 (27) | 34 (23) | 32 (33) | 43 (24) | 23 (26) | ||
| SD/PD | 0 (0) | 6 (3) | 8 (6) | 2 (3) | 5 (4) | 3 (5) | ||
| Response at 2 y | ||||||||
| Observation arm | ||||||||
| CR/CRu | 15 (58) | 37 (43) | 44 (59) | .19 | 21 (43) | 43 (45) | 28 (59) | .17 |
| PR | 4 (15) | 11 (13) | 5 (6) | 5 (10) | 7 (7) | 7 (15) | ||
| SD/PD | 7 (27) | 38 (44) | 26 (35) | 20 (41) | 39 (41) | 11 (23) | ||
| Maintenance arm | ||||||||
| CR/CRu | 21 (72) | 72 (77) | 55 (80) | .61 | 43 (77) | 76 (73) | 27 (73) | .93 |
| PR | 4 (14) | 8 (8) | 3 (4) | 3 (5) | 9 (9) | 3 (8) | ||
| SD/PD | 4 (14) | 14 (15) | 11 (16) | 7 (13) | 14 (14) | 6 (16) | ||
CR indicates complete response; CRu, unconfirmed complete response; PR, partial response; SD/PD, stable disease/progressive disease; and R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.